NEW YORK, April 21, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Cellular Biomedicine (NASDAQ: CBMG), CIFC Corp. (NASDAQ: CIFC), Consumer Portfolio Services (NASDAQ: CPSS), Credit Acceptance (NASDAQ: CACC), and Home Loan Servicing (NASDAQ: HLSS). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
Today's update concerns the following companies:
Full PDF Download Links (you may have to copy and paste the following links into your browser):
CBMG Research Report: ( http://get.analystsreview.com/pdf/?c=Cellular%20Biomedicine&d=21-Apr-2015&s=CBMG ),
CIFC Research Report: ( http://get.analystsreview.com/pdf/?c=CIFC%20Corp&d=21-Apr-2015&s=CIFC),
CPSS Research Report: ( http://get.analystsreview.com/pdf/?c=Consumer%20Portfolio%20Services&d=21-Apr-2015&s=CPSS ),
CACC Research Report: ( http://get.analystsreview.com/pdf/?c=Credit%20Acceptance&d=21-Apr-2015&s=CACC ),
HLSS Research Report: ( http://get.analystsreview.com/pdf/?c=Home%20Loan%20Servicing&d=21-Apr-2015&s=HLSS ).
Analyst Update: Quarterly Results, Acquisitions, and Merger Agreements
Reviewed by: Rohit Tuli, CFA®
U.S. stocks rallied on Monday, triggered by some good first-quarter earnings reports. The NASDAQ gained 1.27% or 62.79 points, to finish at 4,994.60; the Dow Jones Industrial Average advanced 1.17%, or 208.63 points to 18,034.93, and the S&P 500 ended the session at 2,100.40, up 0.92% or 19.22 points. The gains were broad based as all the sectors closed the session in positive. European stocks too edged higher on Monday, as aggressive easing policy in China offsets the impact of Greece turmoil. Major European markets ended the session higher, as Germany's DAX rose 1.74%; France's CAC advanced 0.86%, and Britain's FTSE 100 jumped 0.82%. Meanwhile, Asian markets mostly disappointed on Monday, amid rising concern over slowdown in the Chinese economy. The Shanghai Composite and Japan's Nikkei both closed lower.
Cellular Biomedicine Group, Inc. (Cellular Biomedicine) acquired Chinese PLA General Hospital's ("PLAGH") Chimeric Antigen Receptor T cell (CAR-T) therapy, PLAGH's recombinant expression vector CD19, CD20, CD30 and Human Epidermal Growth Factor Receptor's (EGFR or HER1) Immuno-Oncology patents (all pending), along with Phase I/II clinical data of the aforementioned therapies and manufacturing knowledge.
CIFC Corp.'s (CIFC) posted Economic Net Income (ENI) of $3.3 million during Q4 2014 as compared to $13.0 million in Q4 2013. For the quarter, net income attributable to CIFC stood at $0.8 million versus $4.9 million in the corresponding prior year period. The Company has also declared a cash dividend of $0.10 per share, payable on April 15, 2015, to shareholders of record at the close of business on April 2, 2015.
Consumer Portfolio Services, Inc. (Consumer Portfolio Services) announced its Q4 2014 financial results with net income of $8.0 million, or $0.25 per diluted share, compared to net income of $6.5 million, or $0.21 per diluted share, in Q4 2013. Revenues for the quarter increased to $83.5 million, from $66.6 million in Q4 2013.
Credit Acceptance Corporation (Credit Acceptance) reported net income of $73.0 million, or $3.45 per diluted share, for Q4 2014, compared to net income of $65.9 million, or $2.80 per diluted share, for the same period in 2013. Adjusted net income for the quarter was $69.4 million, or $3.28 per diluted share, compared to $64.3 million, or $2.73 per diluted share in Q4 2013.
Home Loan Servicing Solutions, Ltd. (HLSS) announced a definitive merger agreement with
New Residential Investment Corp., under which the latter will acquire all of the outstanding shares of the Company for $18.25 per share in cash, for a total value of approximately $1.3 billion.
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review